摘要
目的探讨同源框CUT样蛋白1、热休克蛋白90在脑胶质瘤中的表达及对患者预后的影响。方法选取86例脑胶质瘤患者作为观察组,同时选取40例因颅脑外伤行额叶减压手术患者作为对照组,采用蛋白质印迹(Western blot)法检测CUX-1、HSP90蛋白表达,分析CUX-1、HSP90蛋白对脑胶质瘤患者无进展生存期(PFS)的影响。结果观察组患者脑胶质瘤组织中CUX-1、HSP90蛋白相对表达量分别为(1.10±0.26)和(1.13±0.21),均明显高于对照组(P﹤0.01);WHO分级Ⅲ~Ⅳ级脑胶质瘤患者脑胶质瘤组织中CUX-1、HSP90蛋白相对表达量分别为(1.29±0.10)和(1.32±0.14),均明显高于Ⅰ~Ⅱ级(P﹤0.01);CUX-1、HSP90蛋白高表达患者中位PFS分别为25个月(95%CI:23.26~26.74)和25个月(95%CI:23.64~26.36),均明显短于CUX-1、HSP90蛋白低表达患者(P﹤0.01);CUX-1和HSP90蛋白表达呈正相关(r=0.760,P﹤0.05)。结论脑胶质瘤患者脑胶质瘤组织中CUX-1、HSP90蛋白表达上调,与WHO分级有关,且两者间存在正相关关系,同时对患者PFS有影响。
Objective To investigate the expression of cut-like homeobox protein-1 and heat shock protein 90 in glioma and their effects on prognosis.Method A total of 86 patients with glioma were selected as the observation group,and 40 patients with frontal lobe decompression due to craniocerebral trauma were selected as the control group.The protein expression of CUX-1 and HSP90 were detected by Western blot.To analyze the effect of CUX-1,HSP90 expression on progress-free survival(PFS)of patients with glioma.Result The relative expression of CUX-1 and HSP90 proteins in glioma tissues of the observation group were(1.10±0.26)and(1.13±0.21),respectively,which were significantly higher than those of the control group(P<0.01).The relative expression of CUX-1 and HSP90 protein in glioma tissues of patients with WHO grade Ⅲ-Ⅳ were(1.29±0.10)and(1.32±0.14),which were significantly higher than those in grade Ⅰ-Ⅱ(P<0.01).The median PFS of patients with up-regulation of CUX-1 and HSP90 protein was 25 months(95%CI:23.26-26.74)and 25 months(95%CI:23.64-26.36),which were significantly shorter than those of CUX-1 and HSP90 downregulation patients(P<0.01).The expression of CUX-1 and HSP90 protein were positive correlation(r=0.760,P<0.05).Conclusion The expression of CUX-1 and HSP90 proteins in cancer tissues from glioma patients is up-regulated,which is related to the WHO classification and has a positive correlation with the grade.The expression of the two indicators has an impact on the patients’PFS.
作者
仝照磊
王琳
高海锋
TONG Zhaolei;WANG Lin;GAO Haifeng(Department of Neurology,Second People’s Hospital of Xinxiang City,Xinxiang 453002,He’nan,China;Department of Neurosurgery,He’nan Provincial People’s Hospital,Zhengzhou 450003,He’nan,China;Department of Neurosurgery,Affiliated Hospital of Northwest University/Xi’an Third Hospital,Xi’an 710018,Shaanxi,China)
出处
《癌症进展》
2021年第16期1686-1689,共4页
Oncology Progress